Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07521046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis

Study acronym: RopeRux
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Start date: Aug 2026 to Oct 2026 · Eligibility criteria expanded, about 45 words · Secondary endpoints: details revised at 2 of 6 entries · 2 more Show 5 more changesShow less
    • Start date: Aug 2026 to Oct 2026
    • Eligibility criteria expanded, about 45 words
    • Secondary endpoints: details revised at 2 of 6 entries
    • Site details revised
    • Study title shortened, about 3 words
  2. Start date: May 2026 to Aug 2026 Primary completion pushed from May 2029 to Aug 2029 · Completion pushed from May 2030 to Aug 2030v3 Show 2 more changesShow less
    • Primary completion pushed from May 2029 to Aug 2029
    • Completion pushed from May 2030 to Aug 2030
  3. Secondary endpoints: details revised at 2 of 6 entriesv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Trial Details
NCT Number NCT07521046
Lead Sponsor University of Utah
Collaborators: PharmaEssentia
Conditions Myelofibrosis
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov